COMPANY
The Great Pioneer for Incurable Diseases The Great Pioneer for Incurable DiseasesLISCure Biosciences is a clinical-stage pharmaceutical company focusing on “injectable bacteria-mediated cancer immunotherapy” and “oral microbiome therapeutics.”
LISCure Biosciences is a clinical-stage pharmaceutical company focusing on “injectable bacteria-mediated cancer immunotherapy” and “oral microbiome therapeutics.”
TECHNOLOGY
Innovative Platform Technology Based on Microbiology and Genomics Innovative Platform Technology Based on Microbiology and GenomicsThe LMT (LISCure Microbiology-based Technology) platform is used to discover and analyze microorganism-based drug candidates. It consists of a therapeutic screening platform, a microbial optimization platform, and a microbiome database platform.
PIPELINE
Addressing Areas of High Unmet Medical Needs Including Oncology, Liver Diseases, Neuroscience, and Immunology Addressing Areas of High Unmet Medical Needs Including Oncology, Liver Diseases, Neuroscience, and ImmunologyWe are conducting a number of global clinical trials, and we have partnered with reputable research institutes, such as Mayo Clinic and Scripps Research, to jointly research and develop liver disease and immuno-oncology programs.
- Indication
- Product
- Collaborators
- Discovery
- In-Vivo Efficacy
- IND Enabling
- Phase 1
- Phase 2
- Microbiome Therapeutics
-
LIVER DISEASES
LIVER DISEASES
IMMUNOLOGY
NEUROSCIENCE
LIVER DISEASES -
LB-P8
LB-P8
LB-P6
LB-P4
LB-P7 -
-
- Bacteria-mediated
Immunotherapy - ONCOLOGY
-
LB-P2D
LB-P1
LB-P3
LB-P10
LB-P11 -
-
- Bacterial EV
-
NEUROSCIENCE
IMMUNOLOGY -
LB-P4E
LB-P6E -
- Research Collaboration
- 01. Research Collaboration with Mayo Clinic (LB-P7&P8 NASH)
- 02. Research Collaboration with Mayo Clinic (LB-P8 Rare Liver Diseases)
- 03. Research Collaboration with The Scripps Research Institute (LB-P2D Immuno-Oncology)
IR/PR
Check out the Notice